Indication
In adults for the treatment of insufficiently controlled T1DM as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.

Medicine details

Medicine name:
dapagliflozin (Forxiga)
SMC ID:
SMC2185
Pharmaceutical company
AstraZeneca UK Ltd
BNF chapter
Endocrine system
Submission type
Full
Status
Publication due date:
09 September 2019
SMC meeting date:
06 August 2019
Patient group submission deadline:
01 July 2019